logo-loader

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Published: 16:24 06 Oct 2022 BST

 

Lantern Pharma (NASDAQ:LTRN) CEO Panna Sharma joined Steve Darling from Proactive to share news the company has presented preclinical data on the potency of drug candidate LP-284 for mantle cell lymphoma and several other non-Hodgkin’s lymphomas using its RADR technology. Sharma talks more about the results and how LP-284 is the next generation acylfulvene that has a synthetically lethal mechanism of action in cancers with impaired DNA damage repair pathway genes.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

11 minutes ago